All In Biotech

Drug Trial Radar · NCT03196297

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Aug 16, 2017

Primary completion

Jun 22, 2018

Study completion Jun 3, 2020

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

Conditions

  • Haemostasis
  • Haemophilia A

Interventions

  • ConcizumabDrug

    0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase

  • Turoctocog alfaDrug

    Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Bleeding Episodes During at Least 24 Weeks From Treatment OnsetTime frame: During at least 24 weeks from treatment onset

Locations

31 sites in 11 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Indianapolis, Indiana

  • Novo Nordisk Investigational Site

    Oklahoma City, Oklahoma

  • Novo Nordisk Investigational Site

    Nashville, Tennessee

  • Novo Nordisk Investigational Site

    Salt Lake City, Utah

  • Novo Nordisk Investigational Site

    Brest, France

  • Novo Nordisk Investigational Site

    Caen, France

  • Novo Nordisk Investigational Site

    Nantes, France

  • Novo Nordisk Investigational Site

    Bonn, Germany

  • Novo Nordisk Investigational Site

    Homburg, Germany

  • Novo Nordisk Investigational Site

    Milan, Italy

  • Novo Nordisk Investigational Site

    Rome, Italy

  • Novo Nordisk Investigational Site

    Aichi, Japan

  • Novo Nordisk Investigational Site

    Nara, Japan

  • Novo Nordisk Investigational Site

    Tokyo, Japan

  • Novo Nordisk Investigational Site

    Tokyo, Japan

  • Novo Nordisk Investigational Site

    Madrid, Spain

  • Novo Nordisk Investigational Site

    Málaga, Spain

  • Novo Nordisk Investigational Site

    Valencia, Spain

  • Novo Nordisk Investigational Site

    Malmö, Sweden

  • Novo Nordisk Investigational Site

    Solna, Sweden

  • Novo Nordisk Investigational Site

    Bangkok, Thailand

  • Novo Nordisk Investigational Site

    Ankara, Turkey (Türkiye)

  • Novo Nordisk Investigational Site

    Bornova-IZMIR, Turkey (Türkiye)

  • Novo Nordisk Investigational Site

    Edirne, Turkey (Türkiye)

  • Novo Nordisk Investigational Site

    Istanbul, Turkey (Türkiye)

  • Novo Nordisk Investigational Site

    Lviv, Ukraine

  • Novo Nordisk Investigational Site

    Belfast, United Kingdom

  • Novo Nordisk Investigational Site

    Cambridge, United Kingdom

  • Novo Nordisk Investigational Site

    London, United Kingdom

  • Novo Nordisk Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.